Physicians’ Opinions Survey on FDA’s Bydureon Approval

2012-03-06
Published : Mar-2012

Physicians were asked to assess their impressions of Bydureon in terms of efficacy, safety, tolerability, expected use, and other important factors. Key questions are broken down by specialty or familiarity to highlight difference in physician perceptions

Highlights

Datamonitor anticipates that the initial enthusiasm will ultimately be muted once physicians gain experience with the drug. Nevertheless, a once-weekly antidiabetic agent clearly represents an attractive option for type 2 diabetes patients, and physicians expect the drug to be a welcome addition to their armamentarium.

FDA’s Bydureon Approval

Published: February 2012
Price
: Single User License US$3800            Corporate User License – US$9500

                    Request Sample


Your key questions answered
  • Assess physicians’ opinions of Bydureon as compared with Amylin’s twice-daily Byetta (exenatide) and Novo Nordisk’s once-daily Victoza (liraglutide)
  • Determine physicians’ expectations for Bydureon’s uptake, line of therapy, and use in combination with other antidiabetics
  • Evaluate how Bydureon may expand the overall market for GLP-1 agonists

Table of Contents

BYDUREON FDA APPROVAL: PHYSICIAN OPINION
Background

SURVEY RESULTS
Demographics
Limited familiarity with PCPs could present a marketing challenge
Impressions of Bydureon’s efficacy differ based on familiarity
Tolerability issues trump safety concerns among physicians familiar with Bydureon
High expectations for Bydureon use will likely come down with increased experience
Endocrinologists expect to use Bydureon in earlier line of therapy compared to PCPs
Combination use with oral antidiabetics is likely
Physicians expect Bydureon to expand the GLP-1 agonist market
Conclusion

APPENDIX
Report methodology
Datamonitor consulting

Disclaimer

List of Figures

Figure: On average, how many patients with type 2 diabetes do you treat per month?
Figure: How familiar are you with Bydureon (once-weekly exenatide)?
Figure: For each attribute below, please select the one drug that you would prefer to prescribe, based on performance (or predicted performance) on that attribute
Figure: Please select the one drug that you would prefer to prescribe, based on efficacy (HbA1c lowering ability)
Figure: Please rank the following potential safety (and tolerability) issues you are most concerned about with Bydureon on a scale of 1 to 7, where 1 is the issue of greatest concern and 7 is the issue of least concern
Figure: Please select the one drug that you would prefer to prescribe, based on injection device
Figure: Where in the treatment algorithm do you think you will most commonly prescribe Bydureon?
Figure: Please consider your hypothetical Bydureon-treated patient population a year post-launch. What percentage of the Bydureon-treated patient population do you expect to have previously been treated with each of the following options?
Figure: Please choose up to three drug classes with which Bydureon could be used in combination. If there are more than three classes, please select the three most likely
Figure: Please give your opinion on how the introduction of Bydureon, and any other market trends, will impact on the number of patients on GLP-1 agonists in the US

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
More Reports
Title Price Buy Now

Parkinson’s Disease: Epidemiology Forecast to 2026

Parkinson's Disease: Epidemiology Forecast to 2026 Summary Parkinson's disease (PD) is the second most common chronic progressive neurodegenerative disorder in the elderly, affecting 1-2% of individuals ages 65 years and older worldwide. PD is associated with motor symptoms involving bradykinesia, rest tremor, rigidity, and postural disturbances, as well as non-motor symptoms including hyposmia, rapid eye movements, sleep behavior disorder, and depression. Age, genetics, sex, and environmental exposure to pesticides increase the risk of developing PD. Conditions such as depression and anxiety have been identified as comorbidities in PD. For this analysis, GlobalData epidemiologists utilized peer-reviewed studies to construct the 10-year epidemiological forecast for the diagnosed prevale......
$3995

Ovarian Disease Global Clinical Trials Review, H1, 2018

Ovarian Disease Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Ovarian Disease Global Clinical Trials Review, H1, 2018" provides an overview of Ovarian Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Ovarian Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. ......
$2500

Parkinson’s Disease Global Clinical Trials Review, H1, 2018

Parkinson's Disease Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Parkinson's Disease Global Clinical Trials Review, H1, 2018" provides an overview of Parkinson's Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Parkinson's Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical t......
$2500

Penile Cancer Global Clinical Trials Review, H1, 2018

Penile Cancer Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Penile Cancer Global Clinical Trials Review, H1, 2018" provides an overview of Penile Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Penile Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical......
$2500

Ovarian Hyperstimulation Syndrome Global Clinical Trials Review, H1, 2018

Ovarian Hyperstimulation Syndrome Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Ovarian Hyperstimulation Syndrome Global Clinical Trials Review, H1, 2018" provides an overview of Ovarian Hyperstimulation Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Ovarian Hyperstimulation Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using Glob......
$2500

Paroxysmal Nocturnal Hemoglobinuria Global Clinical Trials Review, H1, 2018

Paroxysmal Nocturnal Hemoglobinuria Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Paroxysmal Nocturnal Hemoglobinuria Global Clinical Trials Review, H1, 2018" provides an overview of Paroxysmal Nocturnal Hemoglobinuria clinical trials scenario. This report provides top line data relating to the clinical trials on Paroxysmal Nocturnal Hemoglobinuria. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated us......
$2500

Peptic Ulcers Global Clinical Trials Review, H1, 2018

Peptic Ulcers Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Peptic Ulcers Global Clinical Trials Review, H1, 2018" provides an overview of Peptic Ulcers clinical trials scenario. This report provides top line data relating to the clinical trials on Peptic Ulcers. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical......
$2500

Pancreatic Cancer Global Clinical Trials Review, H1, 2018

Pancreatic Cancer Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Pancreatic Cancer Global Clinical Trials Review, H1, 2018" provides an overview of Pancreatic Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Pancreatic Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials da......
$2500

Partial Seizure Global Clinical Trials Review, H1, 2018

Partial Seizure Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Partial Seizure Global Clinical Trials Review, H1, 2018" provides an overview of Partial Seizure clinical trials scenario. This report provides top line data relating to the clinical trials on Partial Seizure. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. ......
$2500

Osteomyelitis Global Clinical Trials Review, H1, 2018

Osteomyelitis Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Osteomyelitis Global Clinical Trials Review, H1, 2018" provides an overview of Osteomyelitis clinical trials scenario. This report provides top line data relating to the clinical trials on Osteomyelitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy